Welcome to our dedicated page for Halozyme Thrp news (Ticker: HALO), a resource for investors and traders seeking the latest updates and insights on Halozyme Thrp stock.
Halozyme Therapeutics, Inc. (HALO) delivers innovative drug delivery solutions through its proprietary ENHANZE® technology, transforming subcutaneous administration of biologics. This dedicated news hub provides investors and healthcare professionals with essential updates on clinical developments, strategic partnerships, and regulatory milestones.
Access timely press releases covering earnings reports, ENHANZE® licensing agreements, and oncology pipeline advancements. Our curated collection features updates on FDA submissions, collaboration expansions with global pharmaceutical leaders, and technology applications across autoimmune disorders and cancer treatments.
Key updates include partnership announcements with industry leaders, clinical trial progress for subcutaneous therapies, and financial performance insights. The resource serves investors tracking royalty revenue models and analysts monitoring competitive positioning in biopharmaceutical delivery systems.
Bookmark this page for direct access to verified corporate communications and objective reporting on Halozyme's mission to enhance treatment experiences through advanced drug delivery platforms. Regularly updated to reflect the company's latest achievements in patient-centric biotechnology innovation.
Halozyme Therapeutics announced the issuance of European Patent No. 4269578 for its ENHANZE® drug delivery platform. The patent, covering the ENHANZE® rHuPH20 product, extends protection until March 6, 2029, and will be validated in 37 European countries.
This strengthens Halozyme's patent portfolio and maintains the original royalty rate for DARZALEX SC in Europe through March 2029. The new patent does not impact royalties for other ENHANZE® licenses, as their rates already extend beyond 2029.
Halozyme will discuss the new patent and update its 2024 financial guidance and 5-year financial outlook in a conference call on June 6, 2024, at 8:30am ET.
Halozyme Therapeutics (NASDAQ: HALO) announced that CEO Dr. Helen Torley will present and host investor meetings at the Goldman Sachs 45th Annual Global Healthcare Conference.
The presentation is scheduled for June 11, 2024, at 6:20 a.m. PT / 9:20 a.m. ET. A live audio webcast of the presentation will be available on the Investor Relations section of Halozyme's website. Replays will be accessible for 90 days post-conference.
Halozyme Therapeutics announced that Bristol Myers Squibb received an updated Prescription Drug User Fee Act (PDUFA) goal date from the U.S. FDA for their Biologics License Application. This application pertains to the subcutaneous formulation of Opdivo (nivolumab) co-formulated with Halozyme's ENHANZE (rHuPH20). The new target date is December 29, 2024. This formulation aims to cover all previously approved adult, solid tumor Opdivo indications, either as monotherapy or in combination treatment. The application is based on the CheckMate-67T Phase 3 trial, which showed noninferior pharmacokinetics, efficacy, and consistent safety compared to the intravenous version. If approved, it will be the first subcutaneous PD-1 inhibitor.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be participating in upcoming investor conferences with Nicole LaBrosse, the Chief Financial Officer, presenting and hosting investor meetings. The company will be at The Citizens JMP Life Sciences Conference on May 14, 2024, and the Benchmark 2024 Healthcare House Call Virtual Conference on May 21 and May 22, 2024. The presentations will be available via live audio webcasts on the Company's Investor Relations section.
Halozyme reported strong financial performance for the first quarter of 2024 with revenue increasing 21% YoY to $196 million, net income of $77 million, and adjusted EBITDA of $116 million. The company also announced a $750 million share repurchase program and reiterated its 2024 financial guidance, expecting total revenue of $915 - $985 million, representing YOY growth of 10% - 19%, adjusted EBITDA of $535 - $585 million, and non-GAAP diluted EPS of $3.55 - $3.90, showing YOY growth of 28% - 41%. Halozyme's CEO highlighted ongoing partnerships with argenx and Roche, as well as advancements in its ENHANZE technology.
